GLP1R in Parkinson's Disease

NCT03659682 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a medication that targets the GLP1R protein can help improve motor function in people with Parkinson's disease.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 120 people Planned (estimated).

Who can join Ages 40–75 · all sexes

Timeline Started 2019-01 · est. completion 2024-12

What this study is testing ClinicalTrials.gov NCT03659682 ↗

Description as written by the study sponsor.

The purpose of the study is to test the neuroprotective and anti-inflammatory properties of semaglutide in idiopathic Parkinson's disease (PD)

Treatments tested

Semaglutide Drug

subcutaneous, 1.0 mg, weekly, 48 months

Main thing measured	Motor Function
Sponsor	Oslo University Hospital
Conditions studied	Parkinson Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03659682 ↗